Why the study?
Does adjuvant chemotherapy using vincristine, cyclophosphamide, and adriamycin improve disease-free survival in patients with localized Ewing's sarcoma compared to historical controls?
Does adjuvant chemotherapy using vincristine, cyclophosphamide, and adriamycin improve disease-free survival in patients with localized Ewing's sarcoma compared to historical controls?
Adjuvant chemotherapy with vincristine, cyclophosphamide, and adriamycin significantly improves disease-free survival in localized Ewing's sarcoma.
Answers are grounded in this paper and cite their sources.
May support adjuvant chemotherapy in localized Ewing's sarcoma; leaves open confirmation in randomized trials.
Adjuvant chemotherapy using vincristine, cyclophosphamide, and adriamycin was used in 28 patients with localized Ewing's sarcoma. Life-table analysis revealed 55% disease-free survival at 3 years. In contrast, our historical control showed less than 10% long-term survival. Adjuvant chemotherapy appears to control both micrometastasis as well as local residual disease. The present study demonstrates the improved survival with adjuvant chemotherapy including adriamycin, vincristine, and cyclophosphamide, in patients with localized Ewing's sarcoma.
No takes yet. Share an insight, caveat, or question.
Advani et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: